Treatment of Parkinsonism with laevodopa

  • Murphy S. F. 


FIFTY consecutive patients with Parkinson’s disease were treated with maximum tolerated doses of laevodopa for periods of 6 to 18 months. Twenty-four patients gave an excellent response and another fourteen showed significant improvement. Of the major manifestations of the disease, akinesia improved most and tremor least. Evidence of toxicity included gastro-intestinal disturbances, postural hypotension, involuntary movements, and mental changes. The maximum therapeutic response occurred within a dosage range of 3 to 8 g per day and the optimal dose and schedule had to be determined for each individual patient. It is concluded that laevodopa is the most effective agent available at the present time for treatment of Parkinson’s disease, regardless of aetiology or severity.


Dopamine Postural Hypotension Involuntary Movement IRISH Journal Homovanillic Acid 


  1. Anden, N. E. et al. 1966. A quantitative study of the nigroneostriatal dopamine neuron system in the Rat. Acta physiol. Scand. 67: 306–312PubMedCrossRefGoogle Scholar
  2. Barbeau, A., et al. 1961. Excretion of dopamine in diseases of the basal ganglia. Science 133:1706–1707.PubMedCrossRefGoogle Scholar
  3. Barbeau, A. 1961. “Biochemistry of Parkinson’s Distase” in Proceedings of the Seventh International Neurological Congress, Rome: Societa Grafica Romana, Vol. 2, pp. 925–927.Google Scholar
  4. Barbeau, A. 1969. I-Dopa Therapy in Parkinson’s Disease, Canad. med. Ass. J. 101: 59–68.PubMedGoogle Scholar
  5. Bertler, A. and Rosengren, E. 1959. Occurrence and distribution of Catecholamines in Brain. Acta physiol. Scand. 47: 350–361.PubMedGoogle Scholar
  6. Birkmayer, W. and Hornykiewicz, O. 1961. Der L-3, 4-Dioxyphenylalanin (=DOPA)—Effekt beider Parkinson—Akinese, Wien. klin. Wschr. 73: 787–788.PubMedGoogle Scholar
  7. Calne, D. B., et al. 1969. L-Dopa in Postencephalitic Parkinsonism, Lancet 1, 744–746.PubMedCrossRefGoogle Scholar
  8. Calne, D. B., et al. 1969. L-Dopa in Idiopathic Parkinsonism. Lancet 2, 973–976.PubMedCrossRefGoogle Scholar
  9. Cote, L., et al. (unpublished data) cited by Yahr et al., op. cit. (1).Google Scholar
  10. Cotzias, G. C., et al. 1967. Aromatic Amino Acids and Modification of Parkinsonism. New Engl. J. Med. 276: 374–379.PubMedGoogle Scholar
  11. Cotzias, G. A., et al. 1969. Modification of Parkinsonism—Chronic Treatment with I-DOPA. New Engl. J. Med. 280: 337–345.PubMedGoogle Scholar
  12. Ehringer, H., and Hornykiewicz, O. 1960. Verteilung von noradrenalin und dopamin (3-hydroxytyramin) im gehrin des menshen, Klin. Wschr. 38: 1236–1239.PubMedCrossRefGoogle Scholar
  13. Godwin-Austen, R. B., et al. 1969. Effects of L-Dopa in Parkinson’s Disease. Lancet 2, 165–168.PubMedCrossRefGoogle Scholar
  14. Goodwin, F. K., et al. 1970. Administration of a Peripheral Decarboxylase Inhibitor with I-dopa to Depressed Patients. Lancet 1, 908–911.PubMedCrossRefGoogle Scholar
  15. Hoehn, M. M. and Yahr, M. D. 1967. Parkinsonism; Onset, Progression, and Mortality, Neurol. 17: 427–442.CrossRefGoogle Scholar
  16. Hornykiewicz, O. 1966. Dopamine (3-hydroxytyramine) and brain function. Pharmacol. Rev. 18: 925–964.PubMedGoogle Scholar
  17. Johansson, B. and Roose, B. E. 1967. 5-Hydroxyindoleacetic and homovanillic acid levels in the cerebrospinal fluid of healthy volunteers and patients with Parkinson’s syndrome. Life Sciences 6: 1449–1454.PubMedCrossRefGoogle Scholar
  18. Klawans, H. L. and Garvin, J. S. 1969. Treatment of Parkinsonism with L-Dopa. Dis. nerv. Syst. 30: 737–746.PubMedGoogle Scholar
  19. McDowell, F., et al. 1970. Treatment of Parkinson’s Syndrome with I Dihydroxyphenylalanine (Laevodopa). Ann. intern. Med. 72: 29–35.PubMedGoogle Scholar
  20. Mawdsley, C. 1970. Treatment of Parkinsonism with Laevodopa. Brit. med. J. 1, 331–337.PubMedGoogle Scholar
  21. Poirier, J. L. and Sourkes, T. L. 1965. Influence of the Substantia Nigra on the Catecholamine content of the striatum, Brain 88: 181–192.PubMedCrossRefGoogle Scholar
  22. Sano, I., et al. 1960. Die Katechinamine im Zentrainervensystem, Klin. Wschr. 38: 57–62.PubMedCrossRefGoogle Scholar
  23. Yahr, Melvin D., et al. 1969. Treatment of Parkinsonism with Laevodopa, Arch. Neurol, 21: 343–354.Google Scholar

Copyright information

© Springer 1971

Authors and Affiliations

  • Murphy S. F. 
    • 1
  1. 1.Departments of Medicine (Neurology) and Pathology (Neuropathology)St. Vincent’s HospitalWorcester

Personalised recommendations